Alberto Bossi

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher et al. · The Lancet Oncology · 2014 · 1.5K citations · Full text

Urology, Oncology, Docetaxel Chemotherapy +9

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 716 citations · Full text

Factorial Design, Urology, × 2 +9

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer et al. · European Urology · 2017 · 636 citations · Full text

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Neal D. Shore, Fred Saad, Michael S. Cookson et al. · New England Journal of Medicine · 2020 · 413 citations · Full text

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer et al. · European Urology · 2020 · 384 citations · Full text